Relmada Therapeutics Inc(RLMD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.93 | Insider Own | 13.01% | Shs Outstand | 106.7M | Perf Week | 4.36% |
| Market Cap | 0.36B | Forward P/E | - | EPS next Y | -28.11% | Insider Trans | 2.97% | Shs Float | 92.8M | Perf Month | -10.19% |
| Enterprise Value | 0.14B | PEG | - | EPS next Q | -0.14 | Inst Own | 84.43% | Short Float | 13.13% | Perf Quarter | -37.38% |
| Income | -0.06B | P/S | - | EPS this Y | 57.07% | Inst Trans | 16.59% | Short Ratio | 9.27 | Perf Half Y | -54.55% |
| Sales | 0.00B | P/B | 1.73 | EPS next 5Y | 20.09% | ROA | -51.57% | Short Interest | 12.18M | Perf YTD | -30.64% |
| Book/sh | 1.94 | P/C | 1.64 | EPS past 3/5Y | 35.03% 17.54% | ROE | -55.66% | 52W High | -58.13% ($8.00) | Perf Year | 36.73% |
| Cash/sh | 2.04 | P/FCF | - | Sales past 3/5Y | - | ROIC | -29.98% | 52W Low | 55.81% ($2.15) | Perf 3Y | 12.04% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 57.98% | Gross Margin | - | Volatility(W/M) | 5.29% 5.92% | Perf 5Y | -85.68% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.2 | Perf 10Y | -23.17% |
| Dividend Ex-Date | - | Quick Ratio | 29.52 | EPS Q/Q | 61.35% | Profit Margin | - | RSI (14) | 44.01 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 29.52 | Sales Q/Q | - | SMA20 | 1.03% ($3.32) | Beta | 0.6 | Target Price | $10.75 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/6 | SMA50 | -13.93% ($3.89) | Rel Volume | 1.23 | Prev Close | $3.21 |
| Employees | 17 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 44.86% - | SMA200 | -37.51% ($5.36) | Avg Volume(3M) | 1.31M | Price | $3.35 |
| IPO | 2014/6/20 | Option/Short | Yes/Yes | Trades | 5118 | Volume | 1,614,507 | Change | 4.36% |
Relmada Therapeutics (RLMD) is a clinical-stage biotech company headquartered in the U.S. Its core pipeline consists of two key candidates: NDI-0341 (ENDIMV-y01), an intravesical therapy targeting non-muscle-invasive bladder cancer, and sepranolone, a neurosteroid aimed at central nervous system disorders. With no commercialized, approved products on the market, the company operates as an R&D-driven organization whose enterprise value hinges on clinical progress.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded about as much as usual. That is 123% of its average volume.
RLMD has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +57.1% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -85.7%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 84.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #250 of 594 in the industry
Based on market cap of $357M.
CAPR#248 Capricor Therapeutics Inc $362M PER - 
OBIO#249 Orchestra BioMed Holdings Inc $360M PER - RLMD#250 Relmada Therapeutics Inc $357M PER - 
GALT#251 Galectin Therapeutics Inc $357M PER - 
SRZN#252 Surrozen Inc $357M PER - 
FAQ
What kind of company is RLMD?
RLMD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RLMD?
The market cap of RLMD is approximately $357M, ranking 3,457 within its sector.
What is the 52-week high and low for RLMD?
RLMD has recorded a 52-week high of $8.00 and a low of $2.15.
